CS
FSTX

Candriam SCA’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Candriam SCA’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,000
Closed -$237K – 853
2018
Q2 		$237K Hold
5,000
– – ﹤0.01% 751
2018
Q1 		$308K Hold
5,000
– – 0.01% 719
2017
Q4 		$269K Buy
+5,000
New +$297K ﹤0.01% 722

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

Candriam SCA's FSTX Position: Q3 2018 in Review

Candriam SCA sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2018, closing a stake of 5,000 shares — an estimated $237K sold.

Candriam SCA first reported a position in FSTX in Q4 2017 and held it in 3 quarters. The position peaked at $308K in Q1 2018. 51 funds tracked by Wall St. Rank hold FSTX as of Q3 2018.

  • Candriam SCA reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Candriam SCA sold 5,000 F-star Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $237K.
  • Candriam SCA first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
  • Candriam SCA's F-star Therapeutics, Inc. Common Stock position peaked at $308K in Q1 2018.
  • 51 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Candriam SCA's 13F filing for Q3 2018, filed 7 Nov 2018.